REG - GENinCode PLC - Change of Adviser

GenincodeAnnouncement

29/11/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231129:nRSc9689Ua&default-theme=true

RNS Number : 9689U  GENinCode PLC  29 November 2023

 

GENinCode Plc

("GENinCode" or the "Company")

 

Change of Adviser

 

Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused
on the prevention of cardiovascular disease, is pleased to announce the
appointment of Cavendish Capital Markets Limited as Nominated Adviser and
Broker with immediate effect.

 

For more information visit www.genincode.com (http://www.genincode.com)

 

 GENinCode Plc                                         www.genincode.com (http://www.genincode.com) or via Walbrook PR
 Matthew Walls, CEO

 Cavendish Capital Markets Limited (Nomad and Broker)  Tel: +44 (0)20 7397 8900
 Giles Balleny / Dan Hodkinson (Corporate Finance)
 Nigel Birks (ECM)

 Dale Bellis / Michael Johnson (Sales)

 Walbrook PR Limited                                   Tel: 020 7933 8780 or
 Anna Dunphy / Louis Ashe-Jepson / Phillip Marriage                                      genincode@walbrookpr.com (mailto:genincode@walbrookpr.com)

 

About GENinCode:

GENinCode Plc is a UK based company specialising in genetic risk assessment of
cardiovascular disease. Cardiovascular disease is the leading cause of death
and disability worldwide.

 

GENinCode operates business units in the UK, Europe through GENinCode S.L.U,
and in the United States through GENinCode U.S. Inc.

 

GENinCode predictive technology provides patients and physicians with globally
leading preventive care and treatment strategies. GENinCode genetic tests
combine clinical algorithms and bioinformatics to provide advanced patient
risk assessment for coronary heart disease.

 

About Cardiovascular Disease (CVD):

Heart and circulatory disease also known as cardiovascular disease (CVD) is
the leading cause of death globally, taking an estimated 17.9 million lives
each year, with Coronary Heart Disease (CHD) representing the leading
cause of death for men, women, and people of most racial and ethnic groups
in the United States. CVD is a group of disorders of the heart and blood
vessels that include coronary heart disease, cerebrovascular disease,
rheumatic heart disease and other conditions. More than four out of five CVD
deaths are due to heart attacks and strokes, and one third of these deaths
occur prematurely in people under 70 years of age. By 2030 the global cost
of CVD is set to rise from approximately US$863 billion in 2010 to US$1,044
billion and is both a major health issue and global economic burden.

 

Cardiovascular disease, causes a quarter of all deaths in the UK and is the
largest cause of premature mortality in deprived areas and is the single
biggest area where the NHS can save lives over the next 10 years. CVD is
largely preventable, through lifestyle changes and a combination of public
health and action on smoking and tobacco addiction, obesity, tackling alcohol
misuse and food reformulation.

 

The most important behavioural risk factors of heart disease and stroke are
unhealthy diet, physical inactivity, tobacco use and harmful use of alcohol.
The effects of behavioural risk factors may show up in individuals as raised
blood pressure, raised blood glucose, raised blood lipids, and overweight and
obesity. These "intermediate risks factors" can be measured in primary care
facilities and indicate an increased risk of heart attack, stroke, heart
failure and other complications.

 

Identifying those at highest risk of CVDs and ensuring they receive
appropriate treatment can prevent premature deaths. Access to noncommunicable
disease medicines and basic health technologies in all primary health care
facilities is essential to ensure that those in need receive treatment and
counselling.

 

The current standard of care for assessing cardiovascular risk is primarily
based on traditional clinical risk factors such as age, sex, smoking, body
mass, blood pressure and cholesterol levels from which individuals are
categorised as being at low, moderate or high risk of a CVD event (e.g heart
attack/myocardial infarction). This categorisation is imperfect as CVD events
frequently occur in those thought to be at low or moderate risk. The size of
the populations at low or moderate risk are much larger than those at high or
very high risk so whilst the relative risk of a CVD event may be small, the
absolute number of CVD events in low and moderate risk populations is much
greater than the number of events in higher risk categories.

 

Clinicians have for many years recognised the importance of prior CVD events
within the families of their patients because genetic factors contribute to
the development of atherosclerosis and a patient's family history has become a
surrogate for their inherited genetic risk. In recent years, with the advances
of genomics, it has proved possible to add genetic profiling to conventional
CVD risk factors, the combination of the two (genetics and conventional
clinical risk factors) enhancing the predictive capability of patient risk
thereby resulting in a personalised and preventive approach to CVD.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  APPBPBPTMTMTBTJ